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Background. Human immunodeficiency virus (HIV)–infected pregnant women increasingly receive antiretroviral therapy 
(ART) to prevent mother-to-child transmission (PMTCT). Studies suggest HIV-exposed uninfected (HEU) children face higher 
mortality than HIV-unexposed children, but most evidence relates to the pre-ART era, breastfeeding of limited duration, and con-
siderable maternal mortality. Maternal ART and prolonged breastfeeding while on ART may improve survival, although this has not 
been reliably quantified.
Methods. Individual data on 19 219 HEU children from 21 PMTCT trials/cohorts undertaken from 1995 to 2015 in Africa and 
Asia were pooled to estimate the association between 24-month mortality and maternal/infant factors, using random-effects Cox 
proportional hazards models. Adjusted attributable fractions of risks computed using the predict function in the R package “frail-
typack” were used to estimate the relative contribution of risk factors to overall mortality.
Results. Cumulative incidence of death was 5.5% (95% confidence interval, 5.1–5.9) by age 24 months. Low birth weight (LBW 
<2500 g, adjusted hazard ratio (aHR, 2.9), no breastfeeding (aHR, 2.5), and maternal death (aHR, 11.1) were significantly associated 
with increased mortality. Maternal ART (aHR, 0.5) was significantly associated with lower mortality. At the population level, LBW 
accounted for 16.2% of 24-month mortality, never breastfeeding for 10.8%, mother not receiving ART for 45.6%, and maternal death 
for 4.3%; combined, these factors explained 63.6% of deaths by age 24 months.
Conclusions. Survival of HEU children could be substantially improved if public health practices provided all HIV-infected 
mothers with ART and supported optimal infant feeding and care for LBW neonates.
Keywords. HIV-exposed uninfected; children, infants; mortality; Asia; Africa.
 Antiretroviral therapy (ART) to prevent mother-to-child trans-
mission (PMTCT) of human immunodeficiency virus (HIV) 
has dramatically reduced the number of HIV-infected infants 
[1, 2]. As more women living with HIV survive and become 
pregnant, the number of HIV-exposed uninfected (HEU) chil-
dren continues to increase [3]. Several studies have shown that 
HEU children may experience worse health outcomes than 
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HIV-unexposed uninfected (HUU) children in the same setting 
[4–10], although this has not been confirmed elsewhere [11–14]. 
Most evidence relates to the era before widespread use of ART 
for PMTCT and for treatment, when increased mortality in 
HEU children was associated with poor maternal health and 
lack of prolonged breastfeeding. Maternal ART for life and pro-
longed breastfeeding with the protection of ART could amelior-
ate such negative associations [15, 16], but this has not yet been 
reliably quantified.
By pooling available individual data on HEU children from 
clinical trials and observational studies, from both the pre- and 
post-ART era, we assessed mortality risk in HEU children in 
Africa and Asia and associated factors. We also estimated the 
relative importance of identified risk factors in mediating poor 
outcomes among HEU children.
METHODS
In a recent systematic review [17], we electronically searched 
2 bibliographic databases, PubMed and Scopus, for articles 
published from 2004 to 2015 using the following keywords: 
HIV, Mortality, and Child or Infant, without restrictions on 
type or region of study, limited to English and French. Titles 
and abstracts were assessed; retained articles were subject to 
full-text reviews with identification of additional references. 
Additionally, we identified PMTCT trials with potential data 
on mortality in HEU children. A total of 29 studies were iden-
tified, and their principal investigators were contacted. One 
declined participation [18], 5 were unable to share data [5, 19–
22] and 2 did not meet the inclusion criteria [23, 24], leaving 
21 studies for the pooled 24-month mortality analysis: 16 from 
sub-Saharan Africa [4, 8, 25–38] and 5 from Asia [39–42]. Of 
these, 17 were randomized trials and 4 were observational stud-
ies conducted at different times (Supplementary Table S1), with 
varying sample sizes and follow-up durations (Table 1).
Maternal antiretroviral exposure was categorized as none; 
single/double peripartum antiretrovirals for PMTCT; 3-drug 
ART for PMTCT given antenatally and postnatally until cessa-
tion of breastfeeding when breastfeeding or until delivery when 
exclusively formula-fed; or 3-drug ART for life, prescribed be-
yond breastfeeding cessation per World Health Organization 
(WHO) HIV treatment and prevention recommendations 
[43, 44]. Mothers with missing information on antiretroviral 
use (n = 44) were assumed to have followed the relevant study 
protocol [28, 35] and thus categorized into the single/double 
antiretroviral PMTCT. The final HIV status of each child was 
defined by study-specific criteria. In our analyses, each child 
contributed from birth to 24 months of age, with right-censoring 
in case of death, end of study follow-up, and loss to follow-up. 
We restricted analyses to HEU children with information on 
breastfeeding and excluded 457 children with unknown infant 
feeding status. Mortality rates per 100 child-years of follow-up 
were estimated by maternal and child characteristics. We used 
the Kaplan-Meier method to estimate survival curves and the 
log-rank test to test for differences between groups.
Associations between 24-month mortality and the following 
factors were assessed: residence (rural vs urban/peri-urban), sex, 
low birth weight (LBW; <2500  g), breastfeeding (ever/never), 
maternal education (none/primary vs above), maternal age at 
delivery (5-year categories), maternal antiretroviral exposure 
(fixed), and maternal vital status (time-dependent). Children 
known to have initiated breastfeeding but with unknown wean-
ing date (n = 1032) were considered to have been breastfed from 
birth to either age 6 months per WHO feeding guidance at the 
time [45], study exit date, or date of mother’s death, which-
ever occurred first. We used random-effects Cox proportional 
hazards models to estimate the association between 24-month 
mortality and potential risk factors, accounting for heterogen-
eity between studies. The final multivariable model included re-
gion (Africa vs Asia) as a fixed effect and adjusted for maternal 
antenatal CD4 cell count (categorical) because CD4 counts 
and ART eligibility varied widely between studies. Data from 
different sites in Kesho Bora [31] and HIVNET024 [30] were 
treated separately. Missing data were included as a separate cat-
egory to maintain sample size. We used a stepwise-descending 
approach for selection of variables in multivariable models, 
which included variables that were statistically significant in 
univariate analyses (at a P value < .1, except for maternal anti-
retroviral exposure, which was maintained in the model inde-
pendent of statistical significance). In the final model, statistical 
significance was reached when the P value was < .05. We also 
analyzed the association between weaning and survival among 
breastfed children only (n = 13 418), with breastfeeding cessa-
tion defined in a time-varying manner.
We assessed the combined effects of breastfeeding and ma-
ternal 3-drug ART (for PMTCT or for life) on mortality, clas-
sifying observation time for each HEU child into 4 categories 
defined by child being breastfed (yes/no) and mother being on 
3-drug ART (yes/no), with breastfeeding and ART variables 
being time dependent. When the date of ART end was un-
known, ART was assumed to have continued until the weaning 
date or 6 months post-partum [45], whichever came first. The 
association between 24-month mortality and breastfeeding/
maternal 3-drug ART was assessed in multivariable analyses 
using Cox proportional hazards models and allowing for het-
erogeneity between studies/trials and adjusting for region as 
fixed effect and maternal antenatal CD4 cell count and birth 
weight (<2500 g) as categorical variables.
Finally, to investigate the relative contribution of risk factors 
to overall 24-month mortality in HEU children, we estimated 
the adjusted attributable fractions (aAFs) of risks based on our 
final multivariable model [46, 47]. The AF for a given factor 
was the number of deaths attributable to the factor divided by 
the total number of deaths in our population if the prevalence 
of other factors remained at the same level. To do this, we first 
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obtained the total number of deaths at a given time by summing 
the individual predicted probabilities of survival for each child 
based on the predict function in the R package “frailtypack” 
[48], then we subtracted this number from the total popula-
tion to derive the number of deaths. To estimate the number of 
deaths attributable to the exposure of interest, we computed the 
number of deaths in the population as if it was not exposed to 
the factor while exposures to other risk factors were unchanged. 
Nonexposure was simulated by setting all children to the ref-
erence category. For example, for deaths associated with LBW, 
all children were classified into the category of having birth 
weight great than 2500 g. The number of deaths attributable to 
a specific factor was the difference between the total number of 
deaths calculated previously and the number of deaths in the 
unexposed population. We estimated the aAFs of the identi-
fied risk factors at 6, 12, and 24 months of age and computed 
95% confidence intervals (CIs) using bootstrapping [49]. All 
statistical analyses were performed using SAS version 9.3 (SAS 
Institute, Cary, North Carolina). For the estimates of AF, we 
used the R package’s “frailtypack” [48] and “boot” [49] using R 
version 3.3.2 (R Development Core Team, 2004).
RESULTS
A total of 19 219 HEU children were part of the analyses 
(Figure  1). Maternal/child baseline characteristics are shown 
in Table  2. Median child follow-up was 404  days (interquar-
tile range [IQR], 336–712). More than 75% of children were 
born in sub-Saharan Africa, mostly Southern Africa; nearly 
70% were born prior to 2005. Most children were ever breast-
fed (69.8%) for a median 181  days (IQR, 126–365). Maternal 
antiretroviral exposure varied across studies (Supplementary 
Table S2), reflecting the timing of the study and prevailing ART 
and PMTCT recommendations [44]. Overall, 23% of mothers 
received no antiretrovirals, 61% received mono/dual peripar-
tum antiretrovirals for PMTCT, 12% received 3-drug ART for 
PMTCT, and only 4% were on ART for life. Median antenatal 
CD4 count was 405 cells/mm3 (IQR, 280–563); 58% of moth-
ers had a CD4 count >350 cells/mm3 at the first antenatal visit. 
Median antenatal CD4 count in women who received ART for 
life was low at 214 cells/mm3 (IQR, 147–361). Median dur-
ation of ART was 178 (IQR, 152–196) and 443 (IQR, 371–730) 
days for 3-drug ART for PMTCT and ART for life, respectively. 
Information on maternal viral load was missing for 16%; among 
those with available information, median antenatal viral load 
was 4.0 log10 copies/mL (IQR, 3.3–4.6).
HEU Child Mortality
Cumulative incidence of death was 2.1% (394/18 012; 95% CI, 
1.9–2.3), 3.1% (575/17 176; 95% CI, 2.9–3.4), 4.5% (797/12 153; 
95% CI, 4.2–4.8), and 5.5% (884/4245; 95% CI, 5.1–5.9) by age 
3, 6, 12, and 24 months, respectively. Median age at death was 
111 days (IQR, 37–244). Mortality varied from 0% in PHPT-5 
1st  [42] to 17.8% in Ditrame-ANRSb [26] (Table 1). Stratified 
by geographical region (Figure 2), 24-month survival probability 
was significantly higher in Asia than in Africa (P < .0001). Of the 
300 children whose mothers died, 17% (n = 51) did not survive 
after mother’s death. Child mortality declined with increasing 
age at the time of mother’s death: 52% if mother died within 
1 month of delivery, 36% if she died between 1 and 3 months, 
20% between 3 and 6 months, 6% between 6 and 12 months, and 
4% between 12 and 24  months. Mortality was highest among 
children with mothers not being on any antiretrovirals (6.1/100 
child-years), with mortality in single/dual antiretrovirals for 
PMTCT, 3.1/100; 3-drug ART for PMTCT, 2.7/100; and ART for 
life, 3.4/100 child-years. Of note, one- third of the single/dual 
antiretrovirals for PMTCT and the 3-drug ART for PMTCT 
groups, respectively, were comprised of mothers of children in 
Figure 1. Flow chart of the children included in the pooled analyses. Abbreviations: HIV, human immunodeficiency virus; ID, identification.
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PHPT trials where child deaths were rarely observed, which 
might explain lower mortality rates in these 2 groups.
Association With Maternal/Child Characteristics
Univariably, LBW children were at 3-fold risk of dying as were 
never-breastfed children (Table  3). Children whose mother 
had died were 16 times as likely to die compared to children 
whose mothers survived; maternal antiretroviral exposure 
was associated with reduced child mortality, but this did not 
reach statistical significance. Adjusting for region, maternal 
antenatal CD4 count, maternal antiretroviral exposure, and 
maternal vital status, LBW and never breastfeeding remained 
significantly associated with increased mortality (Table 3). The 
association between maternal ART for life and reduced child 
mortality became statistically significant (adjusted hazard ratio 
[aHR], 0.5; 95% CI, 0.3–0.9) after adjusting for maternal CD4 
count (HR, 0.72 in univariate analysis, declining to 0.54 after 
adjusting for maternal CD4 count only). Associations between 
mortality and the other antiretroviral categories did not reach 
statistical significance (single/dual antiretrovirals: aHR, 0.78; 
95% CI, 0.50–1.22 and 3-drug ART for PMTCT: aHR, 0.66; 95% 
CI, 0.39–1.13). Children whose mother had died remained at a 
substantially increased risk of death (aHR, 11.1).
Additional analyses, including ever-breastfed children only 
(n = 13 418) and treating breastfeeding cessation as a time-depend-
ent variable, showed mortality risk to be significantly increased 
after breastfeeding cessation. Adjusting for region, birth weight, 
maternal CD4 count, and maternal antiretroviral exposure, breast-
feeding cessation was associated with a 12.5-fold (95% CI, 10.3–
15.3) risk of death. In this model, children whose mothers received 
3-drug ART (both PMTCT and for life) were at significantly lower 
risk of death (aHR, 0.51; 95% CI, 0.30–0.85 for 3-drug ART for 
PMTCT and aHR, 0.45; 95% CI, 0.22–0.92 for ART for life) than 
children whose mothers did not receive antiretrovirals (ARVs).
Sensitivity Analyses
To investigate the sensitivity of our assumption on 44 women 
with no information on ARV exposure, we ran the analyses and 
Table 2. Baseline Characteristics of the Study Population (N = 19 219)
Child Characteristics
Follow-up duration (days) (median, IQR)
404 336–712
Region (N, %)
East Africa 1620 8.4
Southern Africa 11 769 61.2
West Africa 1397 7.3
South Asia 628 3.3
Southeast Asia 3805 19.8
Residence (N, %)
Rural 1868 9.8
Urban/Peri-urban 17 351 90.2
Access to piped water at home (N, %)
Yes 6182 32.2
No 4268 22.2
Unknown 8769 45.6
Years of birth (N, %)a
1995–1999 4659 24.2
2000–2004 8419 43.8
2005–2009 4852 25.3
2010–2014 1289 6.7
Sex (N, %)
Male 9839 51.2
Female 9376 48.8
Unknown 4 0.0
Birth weight (N, %)
≥2500 g 16 653 86.6
<2500 g 2321 12.1
Unknown 245 1.3
Child ever breastfed (N, %)
Yes 13 418 69.8
No 5801 30.2
Breastfeeding duration (days) (median, IQR) (N = 13 418)
181 126–365
Maternal characteristics
Education (N, %)
None/Primary 8676 45.1
Secondary or above 9688 50.4
Unknown 855 4.5
Maternal age at delivery (years) (N, %)
15–20 2074 10.8
21–25 6159 32.1
26–30 5175 26.9
31–35 2545 13.2
>35 1011 5.3
Unknown 2255 11.7
Maternal ARVs/ART (N, %)
No ARVs 4392 22.8
Single or double ARVs for PMTCT 11 805 61.4
3-drug ART for PMTCT 2248 11.7
ART for life 774 4.0
Antenatal CD4 count above 350 cells/mm3 (N, %)
Yes 11 129 57.9
No 7010 36.5
Unknown 1080 5.6
Antenatal CD4 count (median, IQR) (N = 18 139)
405 280–563
Child Characteristics
Antenatal viral load above 5 log10 copies/mL (N, %)
Yes 2097 10.9
No 14 037 73.0
Unknown 3085 16.1
Antenatal viral load (log10 copies/mL) (median, IQR) (N = 16 134)
4.0 3.3–4.6
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; IQR, interquartile range; 
PMTCT, prevent mother-to-child transmission.
aInformation on the date of birth was not available in HIVNET024 and ZEBS. As the en-
rollment into these studies took place in 2001–2003 and 2001–2004, respectively, these 
children were classified into the 2000–2004 category.
Table 2. Continued
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excluded these women; the aHRs were virtually unchanged. 
Further, 2 additional analyses were carried out to verify the effects 
of the inclusion of 1032 children with no information on wean-
ing date and our assumption on their breastfeeding cessation at 
6 months. After excluding these children, in the model with breast-
feeding treated as a fixed effect, all aHRs were comparable to results 
shown in Table 3 (aHR, 3.0; 95% CI, 2.3–3.9 vs aHR, 2.5; 95% CI, 
2.0–3.2). When breastfeeding was treated as a time-dependent var-
iable, the risk related to breastfeeding cessation increased slightly 
but remained comparable to results presented in Table  3 (aHR, 
16.9; 95% CI, 13.5–21.1 vs aHR, 13.1; 95% CI, 10.7–16.0).
Combined Effects of Maternal ART and Breastfeeding
Mortality by age 24 months differed significantly by breastfeed-
ing and maternal 3-drug ART status at a given time (P < .0001; 
Table  4). Compared to not currently breastfed children with 
mothers not receiving 3-drug ART (category A in Table 4), 
mortality risk in not currently breastfed children with mothers 
receiving 3-drug ART (category  B) was significantly reduced 
(HR, 0.6). In the absence of maternal 3-drug ART, currently 
breastfed children (category  C) were significantly less likely 
to die (HR, 0.07). Currently breastfed children whose mothers 
were receiving 3-drug ART (category D) had the lowest mor-
tality risk (HR, 0.04).
Adjusted Attributable Fractions of Risks
To investigate the impact of LBW, never breastfeeding, mother 
not on 3-drug ART for life, and maternal death, we estimated the 
aAFs of risks based on the parameter estimates obtained from 
our final model (Table 3). Mother not receiving 3-drug ART for 
life accounted for 45.6% (95% CI, 19.1–63.9) of child deaths by 
age 24 months. LBW accounted for an estimated 16.2% of child 
deaths by age 24  months, never breastfeeding for 10.8%, and 
maternal death for 4.3%. Combined, these 4 factors explained 
63.6% (95% CI, 45.7–76.6) of deaths by age 24  months. The 
aAFs of risks at 6 and 12 months related to these 4 factors did 
not significantly differ from those at 24 months (Table 5).
DISCUSSION
Using data from 21 studies/trials undertaken between 1995 
and 2015 in Africa and Asia, our findings suggest that where 
mothers are alive, on ART for life, and breastfeed their infants, 
24-month mortality in HEU children is substantially reduced.
As reported previously [50–52], LBW, prevalent in 12% 
of these HEU children, was a major risk factor for mortality. 
However, the negative consequences of LBW and non-breast-
feeding may be even greater in settings outside the context of 
well-resourced research studies. Almost half of HEU deaths 
occurred in the first 3 months of life and two-thirds before age 
6 months, highlighting the importance of intervening program-
matically in this early period.
The survival of mothers living with HIV had a major effect 
on the survival of HEU children; this association has also been 
reported among HUU children [53]. In our analyses, the death 
of a mother shortly after delivery was most hazardous for the 
survival of her HEU child.
Our results suggest that the risk of mortality in HEU children 
is reduced when mothers are on ART either until breastfeed-
ing cessation or for life. Mother’s initiation and continuation of 
ART likely improves her own health, which in turn increases 
the chances of child survival through better breastfeed-
ing practices, reduced exposure to comorbidities, improved 
mother’s care capacity, and other unmeasured benefits at the 
household level.
Figure 2. Kaplan-Meier estimates of 24-month survival from birth by geographical region.
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The estimated AFs differed from the aHRs. This indicates that 
the impact at the population level, which reflects prevalence 
of risk factors, differs from that at the individual level. The CI 
around the AF estimate of mother not receiving 3-drug ART 
for life was particularly wide, and caution is required in inter-
preting this result. Our estimated AFs show that 36% of HEU 
Table 3. Factors Associated With Mortality Through 24 Months of Age in Human Immunodeficiency Virus–Exposed Uninfected Children (n = 19 219)
Factor
Total Number 
of Children 
(n = 19 219)
Total Number 
of Deaths 
(n = 884)
Mortality 
Rate per 100 
Child-Years of 
Follow-up
Univariate Model Multivariable Model
Hazard 
Ratio 95% CI P Value
Adjusted 
Hazard Ratio 95% CI P Value
Region <.0001 <.0001
Africa 14 786 862 4.6 Ref. Ref.
Asia 4433 22 0.4 0.08 0.04 0.17 0.05 0.02 0.11
Residence 0.22
Rural 1868 101 3.5 Ref.
Urban/Peri-urban 17 351 783 3.7 0.84 0.64 1.11
Sexa 0.28
Male 9839 467 3.8 Ref.
Female 9376 417 3.6 0.93 0.82 1.06
Birth weight <.0001 <.0001
≥2500 g 16 553 613 2.9 Ref. Ref.
<2500 g 2321 246 9.1 3.09 2.66 3.58 2.92 2.51 3.39
Unknown 245 25 8.1 2.21 1.47 3.33 2.40 1.60 3.61
Breastfeeding <.0001 <.0001
Ever breastfed 13 418 700 4.2 Ref. Ref.
Never breastfed 5801 184 2.5 2.76 2.14 3.57 2.48 1.95 3.16
Maternal age at de-
livery (years)
0.42
15–20 2074 103 4.4 Ref.
21–25 6159 276 3.9 0.91 0.73 1.15
26–30 5175 231 3.8 0.91 0.72 1.16
31–35 2545 99 3.2 0.80 0.61 1.06
>35 1011 35 2.8 0.73 0.50 1.08
Unknown 2255 140 3.5 1.25 0.43 3.68
Maternal education 0.03
None/Primary 8676 389 3.7 Ref.
Secondary or above 9688 477 3.7 0.88 0.76 1.03
Unknown 855 18 3.3 0.23 0.05 1.05
Maternal CD4 
count (cells/ 
mm3)
<.0001 <.0001
≥350 11 129 417 3.0 Ref. Ref.
<350 7010  403 4.6 1.58 1.38 1.82 1.43 1.24 1.66
Unknown 1080 64 5.6 1.55 1.16 2.07 1.49 1.12 1,99
Maternal antiretro-
viral category
0.28 0.13
No ARVs 4392 305 6.0 Ref. Ref.
Single or double ARV 
for PMTCT
11 805 469 3.1 0.67 0.42 1.07 0.78 0.50 1.22
3-drug ART for 
PMTCT
2248 73 2.7 0.61 0.34 1.07 0.66 0.39 1.13
ART for life 774 37 3.4 0.72 0.38 1.37 0.51 0.28 0.94
Maternal 
vital status 
(time-dependent)
<.0001 <.0001
Alive b 833 3.5 Ref. Ref.
Dead 51 35.7 15.9 11.9 21.2 11.08 8.25 14.89
Variable trial/study was included in all models as random effects.
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; CI, confidence interval; HR, hazard ratio; PMTCT, prevent mother-to-child transmission.
aExcluding n = 4 with no information on sex.
bNot applicable for time-dependent variables.
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child mortality at age 24 months could not be accounted for by 
the 4 risk factors identified and highlight that HEU children are 
also at risk of death from other common causes of child mor-
tality. The lack of contemporaneous mortality data from HUU 
children meant that we were unable to categorically comment 
whether HEU children are at any greater mortality risk if these 
4 risk factors are fully addressed.
Although the analyses include a large number of HEU chil-
dren from diverse settings, interpretation of findings is hindered 
by lack of detail on potentially important variables including 
gestational age, neonatal care practices (early initiation and type 
of breastfeeding), and household exposure to opportunistic 
infections (such as tuberculosis). These factors may account for 
much of the remaining 36% mortality.
Relatively few women were on ART for life, and studies 
generally followed earlier WHO guidelines on HIV and infant 
feeding, recommending breastfeeding for about 6 months only. 
Although we confirm the associations between reduced mor-
tality risk and maternal ART for life and breastfeeding, our 
data does not allow us to fully capture the complex associations 
between different factors that influence a child’s survival out-
come. The women on ART in our study are a highly select pop-
ulation, and we cannot comment on the extent to which such 
reductions are facilitated by study-specific factors and whether 
such associations would be equally observed in women on ART 
in standard-of-care settings. Further, due to lack of data, we 
were unable to allow for cotrimoxazole prophylaxis and child-
hood immunization, which are used to prevent infectious mor-
bidity in young children.
We were also unable to differentiate small-for-gestational age 
from premature infants in those with LBW. About 11% of all 
infants in Eastern and Southern Africa are born with LBW; in 
Southeast Asia it is around 28% [54]. LBW has been associated 
with HIV infection in pregnant women in sub-Saharan Africa 
and with the protease inhibitor class of ART during pregnancy 
[55–57]. While the primary drivers for LBW may vary by re-
gion and HIV exposure, the relationship between LBW and 
mortality in both HEU and HUU children is clear and strong 
and has immediate programmatic implications.
The combination of 3-drug ART was introduced in about the 
middle of the timespan covered by the studies included; ART 
eligibility criteria varied over time as did inclusion for trials. 
Although we could not allow for these trends, these factors 
could have introduced selection bias. Each study had its own 
criteria for eligibility, including CD4 counts. Data included in 
our analyses were heterogeneous in terms of feeding and dur-
ation of follow-up, which limits our ability to generalize the 
results beyond these studies. Finally, exclusion of 457 children 
whose breastfeeding status was unknown might have led to 
underestimation of mortality rates as almost 29% (132/457) of 
Table 5. Estimated Adjusted Attributable Fractions and 95% Confidence Intervals of Risk Factors for Mortality in Human Immunodeficiency Virus–Exposed 
Uninfected Children at Different Time Points
Expected Number of Deaths Given the Distribution at 6, 12, 
and 24 Months
0–6 Months 0–12 Months 0–24 Months
755 1054 1444
Number 
of Deaths 
Attributable 
to the Risk 
Factor(s)
aAF 
(%) 95% CI
Number 
of Deaths 
Attributable 
to the Risk 
Factor(s)
aAF 
(%) 95% CI
Number 
of Deaths 
Attributable 
to the Risk 
Factor(s)
aAF 
(%)  95% CI
Mother not receiving 3-drug antiretroviral therapy for life 342 47.9 20.0–65.8 466 46.9 15.6–64.9 620 45.6 19.1–63.9
Low birth weight 140 18.5  15.1–21.9 184 17.4  14.2–20.6 234 16.2 13.1–19.2
Breastfeeding never initiated 88 11.7  5.2–19.6 119 11.3  5.0–18.9 157 10.8 4.9–17.9
Mother not being alive 44 5.9  3.1–13.5 53 5.1  2.7–11.5 62 4.3 2.3–9.3
All 4 factors above 486 66.2  48.6–78.4 666 65.0  47.2–77.7 891 63.6 45.7–76.6
Abbreviations: aAF; adjusted attributable fraction; CI, confidence interval.
Table 4. Multivariate Analysis on the Effects of Breastfeeding and Maternal 3-Drug Antiretroviral Therapy on Child Mortality (n = 24 186 child-years)
Category
Child Currently 
Breastfeda
Mother Being on 3-Drug 
Antiretroviral Therapya
Number of 
Child-Years Number of Deaths Adjusted Hazard Ratiob
95% 
Confidence 
Interval P Value
<.0001
A No No 14 119 552 Ref.
B No Yes 1027 44 0.63 0.45 0.87
C Yes No 7874 269 0.08 0.06 0.09
D Yes Yes 1166 19 0.04 0.03 0.07
aTime-dependent variables.
bVariable trial/study was included as random effects. Also adjusted for region, maternal antenatal CD4 count, and birth weight.
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these children died before age 12 months; 105 died before age 
1 month, 17 between age 1 and 3 months, and 10 died thereafter.
We show substantial regional differences in 24-month mor-
tality, which deserves further investigation, as do the issues 
surrounding breastfeeding. Explaining the missing fraction of 
HIV-related and other external mortality risk factors requires 
prospectively collected data from both HEU and HUU popu-
lations. It remains unclear whether HEU infants and children 
are immunologically impaired at a clinically significant 
level or whether increased exposure to opportunistic infec-
tions because of living in HIV-affected households would ex-
plain the missing fraction. Perhaps the most germane question 
is whether increasing rollout of lifelong ART among women 
living with HIV and fully supporting optimal infant feeding 
practices will mitigate the patterns of risks identified in these 
historical cohorts. With more and more women living with HIV 
being initiated on ART, understanding the interactions between 
fetal HIV and ART exposure, the effects of prematurity or 
small-for-gestational age on mortality, and the effects of other 
long-term outcomes including early child development, infec-
tious morbidity, and the risk of noncommunicable diseases will 
be increasingly important.
CONCLUSIONS
Our findings show that not-breastfeeding and LBW were associ-
ated with considerable mortality risk and suggest that maternal 
ART, initiated before or during pregnancy, may substantially re-
duce child mortality in the first 2 years of life. With increasing 
numbers of HIV-infected pregnant women being initiated on 
ART, this would provide hope for reducing overall child mortality 
in settings of high HIV prevalence. The importance of delivering 
effective integrated care so that women living with HIV are not 
only initiated on ART but are also linked with other essential ele-
ments of maternal and child healthcare is clear. Eliminating pedi-
atric HIV and improving the survival, health, and development 
of HEU children should not be separate from improving the 
well-being of mothers and children not affected by HIV, and our 
metric of success needs to evolve to “HIV-free survival and devel-
opment.” While integrated programs and coordinated research 
and monitoring are unquestionably possible, continued global 
investment in these responses is perhaps the greatest challenge.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
Notes
Author contributions. R. B., M. L. N., and N. R. initiated and set the 
objectives of the collaboration, defined the statistical analysis plans, and 
substantially contributed to the writing of the manuscript. S.  A.  under-
took the literature review, managed the data pooling, participated in the 
definition of the statistical analysis plan, performed statistical analysis, and 
wrote the first draft of the paper. M. R. and P. J. substantially contributed to 
the statistical analysis. G. J., J. H., T. F., G. G., L. K., R. S., V. L., S. L., R. C. B., 
T. D., and S. L. C. critically reviewed the manuscript and substantially con-
tributed to the interpretation of the results. All other coauthors reviewed 
the manuscript.
Acknowledgments. BAN: Charles van der Horst, Denise Jamieson; 
Ditrame-ANRSa: Christiane Welffens-Ekra, Philippe Msellati; Ditrame-
ANRSb: Nicolas Meda, Philippe Van de Perre; Ditrame Plus: Marguerite 
Timité-Konan, Clarisse Bosse; Good Start: Mickey Chopra, Debra Jackson, 
Vundli Ramokolo, Ameena Goga; HIVIGLOB: J.  Brooks Jackson, Laura 
A. Guay, Philippa Musoke, Mary Glenn Fowler, Michael C. Mubiru; PEP: 
Mike Urban (University of Stellenbosch); PHPT: Marc Lallemant, principal 
investigator of the PHPT clinical trials, all PHPT coinvestigators, the PHPT 
staff who helped collect and manage the data, and Nicolas Salvadori for the 
preparation of the data-set of the PHPT studies. PROMOTE2: Diane Havlir, 
Theodore Ruel. SWEN: Amita Gupta, Jayagowri Sasty, Harjot K.  Singh; 
ZEBS: The late Moses Sinkala (Lusaka District Health Management Team), 
Chipepo Kankasa (University Teaching Hospital), Donald M. Thea (Boston 
University), Grace M. Aldrovandi (University of California–Los Angeles).
Disclaimer. The World Health Organization  (WHO) had no role in 
the study design, data collection, data analysis, or interpretation of data. 
The findings and conclusions in this paper are those of the authors and do 
not necessarily represent the official position of WHO or the Centers for 
Disease Control and Prevention.
Funding. This work was funded by the WHO.
Potential conflicts of interest. All authors: No reported conflicts of 
interest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to 
the content of the manuscript have been disclosed.
References
1. UNAIDS. Prevention Gap Report. Geneva: UNAIDS, 2016.
2. UNAIDS. On the Fast-track to an AIDS-Free Generation. Geneva: UNAIDS, 2016.
3. Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new global 
challenges in the era of paediatric HIV elimination. Lancet Infect Dis 2016; 
16:e92–e107.
4. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal 
and infant HIV status in Zimbabwe. Pediatr Infect Dis J 2007; 26:519–26.
5. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIV-infected and 
uninfected children of HIV-infected and uninfected mothers in rural Uganda. J 
Acquir Immune Defic Syndr 2006; 41:504–8.
6. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-
infected women randomized to protease versus nucleoside reverse transcriptase 
inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204:506–14.
7. Koyanagi A, Humphrey JH, Moulton LH, et al. Predictive value of weight loss on 
mortality of HIV-positive mothers in a prolonged breastfeeding setting. AIDS Res 
Hum Retroviruses 2011; 27:1141–8.
8. Shapiro RL, Lockman S, Kim S, et al. Infant morbidity, mortality, and breast milk 
immunologic profiles among breast-feeding HIV-infected and HIV-uninfected 
women in Botswana. J Infect Dis 2007; 196:562–9.
9. von Mollendorf C, von Gottberg A, Tempia S, et al. Increased risk for and mor-
tality from invasive pneumococcal disease in HIV-exposed but uninfected infants 
aged <1 year in South Africa, 2009–2013. Clin Infect Dis 2015;60:1346–56.
10. Henderson RA, Miotti PG, Saavedra JM, et al. Longitudinal growth during the 
first 2 years of life in children born to HIV-infected mothers in Malawi, Africa. 
Pediatr AIDS HIV Infect 1996; 7:91–7.
11. Moraleda C, de Deus N, Serna-Bolea C, et al. Impact of HIV exposure on health 
outcomes in HIV-negative infants born to HIV-positive mothers in sub-Saharan 
Africa. J Acquir Immune Defic Syndr 2014; 65:182–9.
12. Landes M, van Lettow M, Chan AK, et al. Mortality and health outcomes of HIV-
exposed and unexposed children in a PMTCT cohort in Malawi. PLoS One 2012; 
7:e47337.
13. Patel D, Bland R, Coovadia H, et  al. Breastfeeding, HIV status and weights in 
South African children: a comparison of HIV-exposed and unexposed children. 
AIDS 2010; 24:437–45.
14. Bailey RC, Kamenga MC, Nsuami MJ, et al. Growth of children according to ma-
ternal and child HIV, immunological and disease characteristics: a prospective 
cohort study in Kinshasa, Democratic Republic of Congo. Int J Epidemiol 1999; 
28:532–40.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article/66/11/1668/4768415 by U
niversite de Bordeaux user on 13 O
ctober 2020
24-Month Survival in HEU Children • CID 2018:66 (1 June) • 1677
15. Ndirangu J, Newell ML, Thorne C, Bland R. Treating HIV-infected mothers 
reduces under 5 years of age mortality rates to levels seen in children of HIV-
uninfected mothers in rural South Africa. Antivir Ther 2012; 17:81–90.
16. Thorne C IP, Chamla D, Romano S, Luo C, Newell ML. Morbidity and mortality 
in HIV-exposed uninfected children. Future Virol 2015;10:1077–100.
17. Arikawa S, Rollins N, Newell ML, Becquet R. Mortality risk and associated factors 
in HIV-exposed, uninfected children. Trop Med Int Health 2016; 21:720–34.
18. Taha TE, Hoover DR, Chen S, et al. Effects of cessation of breastfeeding in HIV-
1-exposed, uninfected children in Malawi. Clin Infect Dis 2011; 53:388–95.
19. Owor M, Mwatha A, Donnell D, et  al. Long-term follow-up of children in the 
HIVNET 012 perinatal HIV prevention trial: five-year growth and survival. J 
Acquir Immune Defic Syndr 2013; 64:464–71.
20. Kafulafula G, Hoover DR, Taha TE, et al. Frequency of gastroenteritis and gastroen-
teritis-associated mortality with early weaning in HIV-1-uninfected children born 
to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010; 53:6–13.
21. Chatterjee A, Bosch RJ, Hunter DJ, Fataki MR, Msamanga GI, Fawzi WW. 
Maternal disease stage and child undernutrition in relation to mortality among 
children born to HIV-infected women in Tanzania. J Acquir Immune Defic Syndr 
2007; 46:599–606.
22. Heidkamp RA, Stoltzfus RJ, Fitzgerald DW, Pape JW. Growth in late infancy 
among HIV-exposed children in urban Haiti is associated with participation in a 
clinic-based infant feeding support intervention. J Nutr 2012; 142:774–80.
23. Sutcliffe CG, Scott S, Mugala N, et al. Survival from 9 months of age among HIV-
infected and uninfected Zambian children prior to the availability of antiretro-
viral therapy. Clin Infect Dis 2008; 47:837–44.
24. Marquez C, Okiring J, Chamie G, et al. Increased morbidity in early childhood 
among HIV-exposed uninfected children in Uganda is associated with breast-
feeding duration. J Trop Pediatr 2014; 60:434–41.
25. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability 
of a short regimen of oral zidovudine to reduce vertical transmission of HIV in 
breastfed children in Côte d’Ivoire and Burkina Faso: a double-blind placebo-con-
trolled multicentre trial. DITRAME Study Group. DIminution de la Transmission 
Mère-Enfant. Lancet 1999; 353:786–92.
26. Msellati P, Meda N, Leroy V, et  al. Safety and acceptability of vaginal disinfec-
tion with benzalkonium chloride in HIV infected pregnant women in West 
Africa: ANRS 049b phase II randomized, double blinded placebo controlled trial. 
DITRAME Study Group. Sex Transm Infect 1999; 75:420–5.
27. Kourtis AP, Wiener J, Kayira D, et  al. Health outcomes of HIV-exposed unin-
fected African infants. AIDS 2013; 27:749–59.
28. Becquet R, Bequet L, Ekouevi DK, et al. Two-year morbidity-mortality and alter-
natives to prolonged breast-feeding among children born to HIV-infected moth-
ers in Côte d’Ivoire. PLoS Med 2007; 4:e17.
29. Onyango-Makumbi C, Bagenda D, Mwatha A, et  al. Early weaning of HIV-
exposed uninfected infants and risk of serious gastroenteritis: findings from two 
perinatal HIV prevention trials in Kampala, Uganda. J Acquir Immune Defic 
Syndr 2010; 53:20–7.
30. Chilongozi D, Wang L, Brown L, et al. Morbidity and mortality among a cohort of 
human immunodeficiency virus type 1-infected and uninfected pregnant women 
and their infants from Malawi, Zambia, and Tanzania. Pediatr Infect Dis J 2008; 
27:808–14.
31. Bork KA, Cournil A, Read JS, et  al. Morbidity in relation to feeding mode in 
African HIV-exposed, uninfected infants during the first 6 mo of life: the Kesho 
Bora study. Am J Clin Nutr 2014; 100:1559–68.
32. Shapiro RL, Kitch D, Ogwu A, et al. HIV transmission and 24-month survival in a 
randomized trial of HAART to prevent MTCT during pregnancy and breastfeed-
ing in Botswana. AIDS 2013; 27:1911–20.
33. Venkatesh KK, de Bruyn G, Marinda E, et  al. Morbidity and mortality among 
infants born to HIV-infected women in South Africa: implications for child 
health in resource-limited settings. J Trop Pediatr 2011; 57:109–19.
34. Natureeba P, Ades V, Luwedde F, et  al. Lopinavir/ritonavir-based antiretroviral 
treatment (ART) versus efavirenz-based ART for the prevention of malaria 
among HIV-infected pregnant women. J Infect Dis 2014; 210:1938–45.
35. Chopra M, Doherty T, Goga A, Jackson D, Persson LA. Survival of infants in the 
context of prevention of mother to child HIV transmission in South Africa. Acta 
Paediatr 2010; 99:694–8.
36. Kammerer B, Kacanek D, Mayondi GK, Lockman S. Pediatric neurodevelopmen-
tal functioning following in utero exposure to triple-NRTI-vs. PI-based ART in a 
randomized trial, Botswana. Washington, D.C.: AIDS, 2012.
37. Rollins NC, Ndirangu J, Bland RM, Coutsoudis A, Coovadia HM, Newell ML. 
Exclusive breastfeeding, diarrhoeal morbidity and all-cause mortality in infants 
of HIV-infected and HIV uninfected mothers: an intervention cohort study in 
KwaZulu Natal, South Africa. PLoS One 2013; 8:e81307.
38. Kuhn L, Sinkala M, Semrau K, et al. Elevations in mortality associated with wean-
ing persist into the second year of life among uninfected children born to HIV-
infected mothers. Clin Infect Dis 2010; 50:437–44.
39. Cressey TR, Punyawudho B, Urien S, et al. Pharmacokinetics of daily nevirap-
ine in neonates at high risk of HIV acquisition. CROI; 22–25 Feb 2016; Boston, 
Massachusetts.
40. Lallemant M, Jourdain G, Le Coeur S, et  al. Single-dose perinatal nevirapine 
plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in 
Thailand. N Engl J Med 2004; 351:217–28.
41. Singh HK, Gupte N, Kinikar A, et  al. High rates of all-cause and gastroenteri-
tis-related hospitalization morbidity and mortality among HIV-exposed Indian 
infants. BMC Infect Dis 2011; 11:193.
42. Lallemant M, Le Coeur S, Sirirungsi W, et al. Randomized noninferiority trial of 
two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV 
in Thailand. AIDS 2015; 29:2497–507.
43. World Health Organization. Antiretroviral drugs for treating pregnant women 
and preventing HIV infection in infants: recommendations for a public health 
approach (2006 revision). Geneva, Switzerland: World Health Organization; 
2006.
44. World Health Organization. Antiretroviral drugs for treating pregnant women 
and preventing HIV infection in infants: recommendations for a public health 
approach (2010 version). Geneva, Switzerland: World Health Organization; 
2010.
45. Inter-agency Task Team on Prevention of HIV Infections in Pregnant Women 
MatI. HIV and infant feeding new evidence and programmatic experience: report 
of a technical consultation. Geneva: WHO, UNICEF, UNAIDS, UNFPA, 2006.
46. Rückinger S, von Kries R, Toschke AM. An illustration of and programs estimat-
ing attributable fractions in large scale surveys considering multiple risk factors. 
BMC Med Res Methodol 2009; 9:7.
47. Benichou J. A review of adjusted estimators of attributable risk. Stat Methods Med 
Res 2001;10:195–216.
48. Rondeau V, Marzroui Y, Gonzalez JR. frailtypack: An R Package for the Analysis 
of Correlated Survival Data with Frailty Models Using Penalized Likelihood 
Estimation or Parametrical Estimation. 2012. 2012; 47:28.
49. Canty A, Ripley BD. boot: Bootstrap R (S-Plus) Functions. 2017.  Available at: 
http://CRAN.R-project.org/package=boot.
50. Wei R, Msamanga GI, Spiegelman D, et  al. Association between low birth 
weight and infant mortality in children born to human immunodeficiency virus 
1-infected mothers in Tanzania. Pediatr Infect Dis J 2004; 23:530–5.
51. Kuhn L, Kasonde P, Sinkala M, et al. Does severity of HIV disease in HIV-infected 
mothers affect mortality and morbidity among their uninfected infants? Clin 
Infect Dis 2005; 41:1654–61.
52. Slyker JA, Patterson J, Ambler G, et al. Correlates and outcomes of preterm birth, 
low birth weight, and small for gestational age in HIV-exposed uninfected infants. 
BMC Pregnancy Childbirth 2014; 14:7.
53. Chikhungu LC, Newell ML, Rollins N. Under-five mortality according to mater-
nal survival: a systematic review and meta-analysis. Bull World Health Organ 
2017; 95:281–7.
54. UNICEF. The state of the world’s children 2016: a fair chance for every child. New 
York: United Nations Children’s Fund, 2016.
55. Braddick MR, Kreiss JK, Embree JB, et al. Impact of maternal HIV infection on 
obstetrical and early neonatal outcome. AIDS 1990; 4:1001–5.
56. Bulterys M, Chao A, Munyemana S, et al. Maternal human immunodeficiency 
virus 1 infection and intrauterine growth: a prospective cohort study in Butare, 
Rwanda. Pediatr Infect Dis J 1994; 13:94–100.
57. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in 
HIV-infected women treated with highly active antiretroviral therapy in Europe. 
AIDS 2004; 18:2337–9.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article/66/11/1668/4768415 by U
niversite de Bordeaux user on 13 O
ctober 2020
